BJU International最新文献

英文中文

Patient-side performance metrics in robotic surgery: international Delphi-based consensus from the Junior European Association of Urology Robotic Section/Young Academic Urologists 机器人手术中患者方面的表现指标：来自欧洲泌尿外科机器人协会/年轻学术泌尿科医师的国际德尔菲共识

IF 3.7 2区医学 Q1 UROLOGY & NEPHROLOGY

BJU International

Pub Date : 2025-01-14 DOI: 10.1111/bju.16638

Christoph Würnschimmel, Marco Paciotti, Mike Wenzel, Carlo Andrea Bravi, Ruben De Groote, Paolo Dell'Oglio, Fabrizio Di Maida, Marcio Covas Moschovas, Federico Piramide, Filippo Turri, Iulia Andras, Gabriele Sorce, Nikolaos Liakos, Anthony Gallagher, Domenico Veneziano, Ton Brouwers, Evangelos Liatsikos, Alberto Breda, Alessandro Larcher

引用次数: 0

Tattoos as a risk factor for bladder cancer: a call for cohort studies 文身是膀胱癌的危险因素：对队列研究的呼吁

IF 4.5 2区医学 Q1 UROLOGY & NEPHROLOGY

BJU International

Pub Date : 2025-01-14 DOI: 10.1111/bju.16648

Nicolas Kluger, Sebastiaan A.S. van der van der Bent

引用次数: 0

Urologists and social media: pitfalls and perils and what to think about before hitting ‘send’ 泌尿科医生和社交媒体：陷阱和危险，在点击“发送”之前要考虑什么

IF 3.7 2区医学 Q1 UROLOGY & NEPHROLOGY

BJU International

Pub Date : 2025-01-13 DOI: 10.1111/bju.16636

Helen W Cui, John Reynard

Objective

To summarise current guidelines from professional bodies relevant to urologists on social media, and to discusses a range of risks associated with social media use. These include the risk of a fitness to practise investigation, breaking the law, loss of employment, and personal risk in the form of harassment and doxxing.

Methods

Review of guidelines and recommendations published by professional bodies revelant to urologists and review of relevant case examples in the medical profession and other relevant professions.

Results

This article finds whereas most doctors will be aware of the risks of posting on public social media platforms, the recent case studies in medical and other contexts have highlighted the risks of disciplinary action from regulators and even criminal investigation in the use of private social media.

Conclusion

Although the majority of urologists are unlikely to violate ethical and good medical practice principles in their use of social media, this article serves as a reminder of the potential consequences based on real-life case examples.

总结与泌尿科医生在社交媒体上相关的专业机构的现行指导方针，并讨论与社交媒体使用相关的一系列风险。这些风险包括适合从事调查的风险、违法风险、失业风险以及以骚扰和骚扰的形式出现的个人风险。

{"title":"Urologists and social media: pitfalls and perils and what to think about before hitting ‘send’","authors":"Helen W Cui, John Reynard","doi":"10.1111/bju.16636","DOIUrl":"10.1111/bju.16636","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To summarise current guidelines from professional bodies relevant to urologists on social media, and to discusses a range of risks associated with social media use. These include the risk of a fitness to practise investigation, breaking the law, loss of employment, and personal risk in the form of harassment and doxxing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Review of guidelines and recommendations published by professional bodies revelant to urologists and review of relevant case examples in the medical profession and other relevant professions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>This article finds whereas most doctors will be aware of the risks of posting on public social media platforms, the recent case studies in medical and other contexts have highlighted the risks of disciplinary action from regulators and even criminal investigation in the use of private social media.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Although the majority of urologists are unlikely to violate ethical and good medical practice principles in their use of social media, this article serves as a reminder of the potential consequences based on real-life case examples.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"135 3","pages":"390-398"},"PeriodicalIF":3.7,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bju.16636","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spatial distribution and subtype‐specific expression patterns of Nectin‐4 in muscle‐invasive bladder cancer 肌浸润性膀胱癌中Nectin - 4的空间分布和亚型特异性表达模式

IF 4.5 2区医学 Q1 UROLOGY & NEPHROLOGY

BJU International

Pub Date : 2025-01-13 DOI: 10.1111/bju.16643

Csilla Olah, Lara Sichward, Boris Hadaschik, Christopher Darr, Viktor Grünwald, Ulrich Krafft, Barbara T. Grünwald, Osama Mahmoud, Mulham Al‐Nader, Peter Nyirady, Henning Reis, Tibor Szarvas

ObjectiveTo investigate the expression patterns of Nectin‐4, the target molecule of the antibody‐drug conjugate enfortumab vedotin (EV), in relation to histological and molecular subtypes of urothelial bladder cancer (UBC).Patients and MethodsWe assessed the protein expression patterns of Nectin‐4 in a spatially organised tissue microarray containing 1386 tissue cores from 314 consecutive patients with UBC who underwent radical cystectomy (2005–2018). Results were correlated with clinicopathological and follow‐up data, as well as with different spatial locations (tumour central vs tumour‐normal interface and primary tumour vs lymph node [LN] metastases). Additionally, we correlated Nectin‐4 expression levels with histological and molecular subtypes. Finally, we assessed the value of Nectin‐4 expression for predicting the efficacy of platinum therapy in the peri‐operative setting.ResultsNectin‐4 expression was observed in 63% of primary tumours and 87% of LN metastases, with significantly higher levels in LNs. Of the histological subtypes, the micropapillary (58%) and pure urothelial histologies (30%) were associated with the highest Nectin‐4 positivity, while the sarcomatoid (17%), squamous (15%) and small/cell‐neuroendocrine (0%) subtypes exhibited the lowest. Nectin‐4 immunopositivity rates were significantly higher in luminal (urothelial‐like [42%] and genomically unstable [34%] Lund subtypes) compared to the basal (5%) or mesenchymal (0%) molecular subtypes. Higher Nectin‐4 expression levels were associated with lower tumour stage but showed no association with overall survival. Finally, patients with low Nectin‐4 expression tended to derive more benefit from platinum‐based chemotherapy in both adjuvant and neoadjuvant settings (P < 0.001, P = 0.067).ConclusionOur results revealed a low spatial heterogeneity of Nectin‐4 expression within the primary tumour. In contrast, differential Nectin‐4 expression was found in the context of histological and molecular subtypes. Nectin‐4‐expressing tumours may show varying sensitivity to both EV and platinum‐based chemotherapy.

目的探讨抗体-药物偶联物（EV）靶分子Nectin - 4的表达模式与尿路上皮性膀胱癌（UBC）组织学和分子亚型的关系。患者和方法我们在空间组织组织微阵列中评估了Nectin‐4的蛋白表达模式，该微阵列包含来自314例连续接受根治性膀胱切除术的UBC患者的1386个组织核心（2005-2018）。结果与临床病理和随访数据以及不同的空间位置（肿瘤中心与肿瘤正常界面、原发性肿瘤与淋巴结转移）相关。此外，我们将Nectin‐4的表达水平与组织学和分子亚型相关联。最后，我们评估了Nectin - 4表达对围手术期铂治疗疗效的预测价值。结果在63%的原发肿瘤和87%的淋巴结转移中观察到nectin‐4的表达，在淋巴结转移中表达水平显著升高。在组织学亚型中，微乳头状（58%）和纯尿路上皮（30%）与最高的Nectin - 4阳性相关，而肉瘤样（17%）、鳞状（15%）和小/细胞-神经内分泌（0%）亚型表现最低。与基础（5%）或间充质（0%）分子亚型相比，管腔（尿路上皮样[42%]和基因组不稳定[34%]Lund亚型）的Nectin - 4免疫阳性率明显更高。较高的Nectin - 4表达水平与较低的肿瘤分期相关，但与总生存期无关。最后，低Nectin - 4表达的患者倾向于在辅助和新辅助环境下从铂基化疗中获得更多益处(P <；0.001, p = 0.067)。结论：我们的研究结果显示，在原发肿瘤中，Nectin - 4的表达具有较低的空间异质性。相反，在组织学和分子亚型的背景下发现了差异的Nectin‐4表达。表达Nectin - 4的肿瘤可能对EV和铂基化疗表现出不同的敏感性。

{"title":"Spatial distribution and subtype‐specific expression patterns of Nectin‐4 in muscle‐invasive bladder cancer","authors":"Csilla Olah, Lara Sichward, Boris Hadaschik, Christopher Darr, Viktor Grünwald, Ulrich Krafft, Barbara T. Grünwald, Osama Mahmoud, Mulham Al‐Nader, Peter Nyirady, Henning Reis, Tibor Szarvas","doi":"10.1111/bju.16643","DOIUrl":"https://doi.org/10.1111/bju.16643","url":null,"abstract":"ObjectiveTo investigate the expression patterns of Nectin‐4, the target molecule of the antibody‐drug conjugate enfortumab vedotin (EV), in relation to histological and molecular subtypes of urothelial bladder cancer (UBC).Patients and MethodsWe assessed the protein expression patterns of Nectin‐4 in a spatially organised tissue microarray containing 1386 tissue cores from 314 consecutive patients with UBC who underwent radical cystectomy (2005–2018). Results were correlated with clinicopathological and follow‐up data, as well as with different spatial locations (tumour central vs tumour‐normal interface and primary tumour vs lymph node [LN] metastases). Additionally, we correlated Nectin‐4 expression levels with histological and molecular subtypes. Finally, we assessed the value of Nectin‐4 expression for predicting the efficacy of platinum therapy in the peri‐operative setting.ResultsNectin‐4 expression was observed in 63% of primary tumours and 87% of LN metastases, with significantly higher levels in LNs. Of the histological subtypes, the micropapillary (58%) and pure urothelial histologies (30%) were associated with the highest Nectin‐4 positivity, while the sarcomatoid (17%), squamous (15%) and small/cell‐neuroendocrine (0%) subtypes exhibited the lowest. Nectin‐4 immunopositivity rates were significantly higher in luminal (urothelial‐like [42%] and genomically unstable [34%] Lund subtypes) compared to the basal (5%) or mesenchymal (0%) molecular subtypes. Higher Nectin‐4 expression levels were associated with lower tumour stage but showed no association with overall survival. Finally, patients with low Nectin‐4 expression tended to derive more benefit from platinum‐based chemotherapy in both adjuvant and neoadjuvant settings (P < 0.001, P = 0.067).ConclusionOur results revealed a low spatial heterogeneity of Nectin‐4 expression within the primary tumour. In contrast, differential Nectin‐4 expression was found in the context of histological and molecular subtypes. Nectin‐4‐expressing tumours may show varying sensitivity to both EV and platinum‐based chemotherapy.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"2 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alkalinised lidocaine as an anaesthetic before onabotulinumtoxinA injections. a randomised trial 碱化利多卡因在肉毒杆菌毒素注射前用作麻醉剂。随机试验

IF 4.5 2区医学 Q1 UROLOGY & NEPHROLOGY

BJU International

Pub Date : 2025-01-11 DOI: 10.1111/bju.16647

Meryam El Issaoui, Marlene Elmelund, Niels Klarskov

ObjectivesTo evaluate the effect of intravesical alkalinised lidocaine as an anaesthetic treatment on procedural pain during intradetrusor onabotulinumtoxinA (BTX‐A) injections for overactive bladder.Patients and MethodsThis single‐centre, randomised, double‐blind, placebo‐controlled two period crossover trial was conducted on women scheduled for BTX‐A injections at our outpatient urogynaecology clinic between September 2022 and May 2024. Patients were randomly assigned (1:1) to receive either alkalinised lidocaine or placebo during the first treatment period. Alkalinised lidocaine solution comprised lidocaine hydrochloride (20 mg/mL, 20 mL), sodium hydrogen carbonate (1 mmoL/mL, 10 mL), and sodium chloride (9 g/L, 10 mL). The matching placebo was sodium chloride (9 g/L, 40 mL). The primary outcome measure was procedural pain rated on a 100‐mm visual analogue scale (VAS). Secondary outcomes included adverse effects such as post‐void residual urine volumes requiring catheterisation, urinary tract infection, haematuria 1 week after treatment, and patient satisfaction measured on a 5‐point scale. During the second treatment period, patients received the alternative intervention.ResultsWe enrolled 50 patients, of which 41 were eligible for per‐protocol analyses. The mean VAS score was significantly lower following intravesical alkalinised lidocaine (mean 21.3 mm, 95% confidence interval [CI] 14.7–27.8 mm) compared to placebo (mean 41.6 mm, 95% CI 35.0–48.1 mm) with a mean difference of −20.3 mm (95% CI −29.2 to −11.5 mm; P < 0.001). Adverse events and patient satisfaction did not significantly differ between the alkalinised lidocaine and placebo treatments (P = 0.825 and P = 0.138, respectively).ConclusionsIntravesical instillation of alkalinised lidocaine before BTX‐A injections significantly reduced VAS pain scores compared to placebo (ClinicalTrials.gov identifier: NCT05415865).

目的探讨膀胱内碱化利多卡因麻醉对膀胱过度活动症患者肌内注射肉毒杆菌毒素A （BTX‐A）时手术性疼痛的影响。患者和方法这项单中心、随机、双盲、安慰剂对照的两期交叉试验于2022年9月至2024年5月在我们的门诊泌尿妇科诊所进行了BTX - A注射。在第一个治疗期间，患者被随机分配（1:1）接受碱化利多卡因或安慰剂。碱化利多卡因溶液由盐酸利多卡因（20mg /mL, 20ml）、碳酸氢钠（1mmol /mL, 10ml）、氯化钠（9g /L, 10ml）组成。配套安慰剂为氯化钠（9 g/L, 40 mL）。主要结局指标是100毫米视觉模拟量表（VAS）评定的程序性疼痛。次要结局包括不良反应，如需要导尿的空后残留尿量、尿路感染、治疗后1周血尿，以及以5分制测量的患者满意度。在第二个治疗期，患者接受替代干预。结果：我们纳入了50例患者，其中41例符合每个方案分析的条件。膀胱内碱化利多卡因VAS评分（平均21.3 mm， 95%可信区间[CI] 14.7-27.8 mm）显著低于安慰剂（平均41.6 mm, 95% CI 35.0-48.1 mm），平均差异为- 20.3 mm (95% CI - 29.2至- 11.5 mm；P & lt;0.001)。碱化利多卡因和安慰剂治疗的不良事件和患者满意度无显著差异（P = 0.825和P = 0.138）。结论：与安慰剂相比，BTX‐A注射前膀胱内灌注碱化利多卡因可显著降低VAS疼痛评分（ClinicalTrials.gov识别码：NCT05415865）。

{"title":"Alkalinised lidocaine as an anaesthetic before onabotulinumtoxinA injections. a randomised trial","authors":"Meryam El Issaoui, Marlene Elmelund, Niels Klarskov","doi":"10.1111/bju.16647","DOIUrl":"https://doi.org/10.1111/bju.16647","url":null,"abstract":"ObjectivesTo evaluate the effect of intravesical alkalinised lidocaine as an anaesthetic treatment on procedural pain during intradetrusor onabotulinumtoxinA (BTX‐A) injections for overactive bladder.Patients and MethodsThis single‐centre, randomised, double‐blind, placebo‐controlled two period crossover trial was conducted on women scheduled for BTX‐A injections at our outpatient urogynaecology clinic between September 2022 and May 2024. Patients were randomly assigned (1:1) to receive either alkalinised lidocaine or placebo during the first treatment period. Alkalinised lidocaine solution comprised lidocaine hydrochloride (20 mg/mL, 20 mL), sodium hydrogen carbonate (1 mmoL/mL, 10 mL), and sodium chloride (9 g/L, 10 mL). The matching placebo was sodium chloride (9 g/L, 40 mL). The primary outcome measure was procedural pain rated on a 100‐mm visual analogue scale (VAS). Secondary outcomes included adverse effects such as post‐void residual urine volumes requiring catheterisation, urinary tract infection, haematuria 1 week after treatment, and patient satisfaction measured on a 5‐point scale. During the second treatment period, patients received the alternative intervention.ResultsWe enrolled 50 patients, of which 41 were eligible for per‐protocol analyses. The mean VAS score was significantly lower following intravesical alkalinised lidocaine (mean 21.3 mm, 95% confidence interval [CI] 14.7–27.8 mm) compared to placebo (mean 41.6 mm, 95% CI 35.0–48.1 mm) with a mean difference of −20.3 mm (95% CI −29.2 to −11.5 mm; P < 0.001). Adverse events and patient satisfaction did not significantly differ between the alkalinised lidocaine and placebo treatments (P = 0.825 and P = 0.138, respectively).ConclusionsIntravesical instillation of alkalinised lidocaine before BTX‐A injections significantly reduced VAS pain scores compared to placebo (ClinicalTrials.gov identifier: NCT05415865).","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"58 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142961227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results 吉西他滨和多西他赛治疗高危非肌浸润性膀胱癌：EuroGemDoce组结果

IF 4.5 2区医学 Q1 UROLOGY & NEPHROLOGY

BJU International

Pub Date : 2025-01-11 DOI: 10.1111/bju.16645

Pietro Scilipoti, Mattia Longoni, Mario de Angelis, Paolo Zaurito, Albane Massiet, Daniele Dutto, Francesco Soria, Mario Álvarez-Maestro, Alfredo Aguilera Bazán, Benjamin Pradere, Tobias Klatte, Roberto Contieri, Rodolfo Hurle, Wojciech Krajewski, José Daniel Subiela, Renate Pichler, Aleksandra Szostek, Gautier Marcq, José Luis Rodríguez Elena, Javier Aranda, Paolo Gontero, Morgan Rouprêt, Shahrokh F. Shariat, Andrea Necchi, Francesco Montorsi, Alberto Briganti, Evanguelos Xylinas, Marco Moschini, ,

To evaluate the oncological efficacy and safety of sequential intravesical gemcitabine/docetaxel (Gem/Doce) therapy in a European cohort of patients with high-risk and very-high-risk non-muscle-invasive bladder cancer (NMIBC) after previous Bacillus Calmette–Guérin (BCG) treatment.

在欧洲一组高风险和极高风险非肌浸润性膀胱癌（NMIBC）患者中，经卡介苗（BCG）治疗后，序贯膀胱内注射吉西他滨/多西他赛（Gem/Doce）治疗的肿瘤学疗效和安全性。

引用次数: 0

Comparison of serum and plasma microRNA expression levels in patients with germ cell tumours 生殖细胞肿瘤患者血清和血浆microRNA表达水平的比较

IF 4.5 2区医学 Q1 UROLOGY & NEPHROLOGY

BJU International

Pub Date : 2025-01-09 DOI: 10.1111/bju.16644

Fady Baky, Richard S. Matulewicz, Andrea Knezevic, Jahwa Hossain, Brandon Williams, Anna Lee, Joel Sheinfeld, Nicole Liso, Rachel So, Alisa Valentino, Fei Ye, Samuel A. Funt, Darren R. Feldman

Click on the article title to read more.

点击文章标题阅读更多内容。

引用次数: 0

Navigating choices: understanding the decision-making journey of patients with localised kidney cancer 导航选择：了解局部肾癌患者的决策过程

IF 4.5 2区医学 Q1 UROLOGY & NEPHROLOGY

BJU International

Pub Date : 2025-01-08 DOI: 10.1111/bju.16635

Katharina Beyer, Lionne D.F. Venderbos, Monique J. Roobol, Rachel H. Giles, Paul Verhagen, Ravi Barod, Lisa M. Wintner, Michael A.S. Jewett, Mieke Van Hemelrijck, Netty Kinsella

To explore patients’ experience of decision making regarding treatment of localised kidney cancer.

探讨局部肾癌患者治疗决策的经验。

引用次数: 0

Impact of intraprostatic PSMA maximum standardised uptake value following prostatectomy: a systematic review and meta-analysis 前列腺切除术后前列腺内PSMA最大标准化摄取值的影响：系统回顾和荟萃分析

IF 4.5 2区医学 Q1 UROLOGY & NEPHROLOGY

BJU International

Pub Date : 2025-01-07 DOI: 10.1111/bju.16608

David C. Chen, Siyu Huang, Nathan Papa, Shankar Siva, Damien M. Bolton, Nathan Lawrentschuk, Louise Emmett, Declan G. Murphy, Michael S. Hofman, Marlon L. Perera

To perform a systematic review and meta-analysis to assess the relationship between intraprostatic maximum standardised uptake value (SUV_max) of the dominant prostatic lesion as measured on preoperative prostate-specific membrane antigen (PSMA) positron emission tomography (PET) with radical prostatectomy International Society of Urological Pathology (ISUP) Grade Group, pathological tumour (pT) staging, and biochemical recurrence (BCR).

通过系统回顾和荟萃分析，评估术前前列腺特异性膜抗原（PSMA）正电子发射断层扫描（PET）测量的显性前列腺病变的前列腺内最大标准化摄取值（SUVmax）与根治性前列腺切除术之间的关系。国际泌尿外科病理学会（ISUP）分级组、病理肿瘤（pT）分期和生化复发（BCR）。

引用次数: 0

HKUA ASM 2024 abstracts hkkua ASM 2024摘要

IF 3.7 2区医学 Q1 UROLOGY & NEPHROLOGY

BJU International

Pub Date : 2025-01-07 DOI: 10.1111/bju.16603

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

BJU International

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀